Edoxaban

Chemical formula: C₂₄H₃₀ClN₇O₄S  Molecular mass: 548.06 g/mol  PubChem compound: 10280735

Therapeutic indications

Edoxaban is indicated for:

Prevention of stroke and systemic embolism in nonvalvular atrial fibrillation (NVAF)

Population group: only adults (18 - 65 years old)

Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prevention of stroke and systemic embolism in nonvalvular atrial fibrillation (NVAF)

Population group: only elderly (65 years old or older)

Prevention of stroke and systemic embolism in patients age ≥75 years with nonvalvular atrial fibrillation (NVAF).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment and prevention of deep vein thrombosis (DVT), pulmonary embolism (PE)

Population group: only adults (18 years old or older)

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Edoxaban is contraindicated in the following cases:

Hepatic disease associated with coagulopathy

Blood coagulation disorder due to liver disease

Pregnancy

Pregnancy

Lactation

Lactation

Uncontrolled severe hypertension

Hypertensive crisis

Anticoagulants

Antithrombotic agents

Bleeding

Bleeding

Gastrointestinal ulceration, malignant neoplasms at high risk of bleeding, trauma or operation at CNS, eyes

at least one of
Gastrointestinal ulcer
Malignant tumour and additionally High risk of hemorrhage

Traumatic injury
Procedure on central nervous system
Surgical procedure on eye proper
Intracranial hemorrhage
Esophageal varices
Congenital arteriovenous malformation
Aneurysm

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: LIXIANA Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈